BASF Pharma Solutions produces innovative excipients of outstanding quality and performance. With a global team of industry experts and digital solutions, such as the Virtual Pharma Assistants, BASF supports its customers in developing efficient, cost-effective, and reliable formulations.
Equipped with an in-depth understanding of multiple technologies and applications, BASF has the knowledge and resources to make drug delivery and drug product manufacturing safer and more sustainable.
We are constantly developing new excipients and using digital technology to speed up and reduce risks in formulation design. For example, we introduced an all-in-one coprocessed excipient that can be easily blended with your chosen active pharmaceutical ingredient (API) and compressed into tablets with just two simple steps. This simplified formulation can help bring drugs to market faster.
Our free Virtual Formulation Assistant, ZoomLabTM, includes tools for predicting API solubility, as well as the polymers and solvents you may need. Additionally, you can assess potential solid-state incompatibilities between your API and excipient, or excipient-excipient. These tools can reduce risks in formulation design and save time in research and development.
As APIs become more complex, we recognize the need for Advanced Manufacturing Technologies to overcome challenges with solubility whilst achieving supply chain resiliency. We offer a complete solution package that includes excipients specifically designed for these technologies, such as continuous hot melt extrusion, along with the expertise to guide you in using these excipients all the way to the final dosage form.
Our commitment to high quality is constantly increasing. We collaborate with regulatory and change agent bodies like IPEC to understand industry concerns and their potential impact on patients. As an example, we have proactively proposed technical solutions to our customers prior to the ban on titanium dioxide in nutraceuticals. We were also among the first suppliers to provide nitrosamine risk assessments for our entire portfolio. Initially, we shared risk assessments on nitrite and nitrate levels, along with our LOQ. Then, in response to customer feedback, we have further lowered our LOQs and openly shared our analytical methods to ensure accurate calculations and high product quality over time.
Sustainability is a top priority for us, as evidenced by our Verbund structure that enables efficient raw material usage and waste stream management. In the pharmaceutical sector, we consider the entire value chain, from sourcing materials to packaging and distribution. For instance, in our Lipids portfolio, we exclusively source materials from RSPO-certified vendors to combat deforestation. In our ibuprofen portfolio, we have reduced emissions by over 20% through closed-loop recycling and greener catalysts.
Our efforts in sustainability are just the beginning. We will continue to reduce our carbon emissions and bring to the market green excipients that support the development of the “tablets of the future”.
READ MORE